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Objectives The purpose of this study was to present radial and saphenous vein graft (SVG) occlusion results more than
5 years following coronary artery bypass surgery.
Background In the RAPS (Radial Artery Patency Study) study, complete graft occlusion was less frequent in radial artery com-
pared with SVG 1 year post-operatively while functional occlusion (Thrombolysis In Myocardial Infarction flow
grade 0, 1, 2) was similar.
Methods A total of 510 patients 80 years of age undergoing primary isolated nonemergent coronary artery bypass graft-
ing with 3-vessel disease were initially enrolled in 9 Canadian centers. Target vessels for the radial artery and
study SVG were the right and circumflex coronary arteries, which had 70% proximal stenosis. Within-patient
randomization was performed; the radial artery was randomized to either the right or circumflex territory and the
study SVG was used for the other territory. The primary endpoint was functional graft occlusion by invasive an-
giography at least 5 years following surgery. Complete graft occlusion by invasive angiography or computed to-
mography angiography was a secondary endpoint.
Results A total of 269 patients underwent late angiography (234 invasive angiography, 35 computed tomography an-
giography) at a mean of 7.7  1.5 years after surgery. The frequency of functional graft occlusion was lower in
radial arteries compared with SVGs (28 of 234 [12.0%] vs. 46 of 234 [19.7%]; p  0.03 by McNemar’s test).
The frequency of complete graft occlusion was also significantly lower in radial compared with SVGs (24 of 269
[8.9%] vs. 50 of 269 [18.6%]; p  0.002).
Conclusions Radial arteries are associated with reduced rates of functional and complete graft occlusion compared with
SVGs more than 5 years following surgery. (Multicentre Radial Artery Patency Study: 5 Year Results;
NCT00187356) (J Am Coll Cardiol 2012;60:28–35) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.037The RAPS (Radial Artery Patency Study) study is a
multicentre randomized clinical trial comparing the longi-
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2012, accepted March 19, 2012.tudinal angiographic patency of the radial artery and saphe-
nous vein (1). We previously reported that 1 year after
surgery, the primary endpoint of complete graft occlusion
was reduced in the radial artery compared with the study
saphenous vein graft (SVG) (8.2% vs. 13.6%, p  0.009)
(2). The treatment effect was similar in multivariable
models (3). The purpose of this investigation is to report
on the patency rates of the radial artery and saphenous
vein more than 5 years following surgery. Although
complete graft occlusion is the standard endpoint used in
SVG occlusion studies, radial grafts with diffuse narrow-
ing or reduced flow would be considered patent by this
definition. The primary endpoint for the late study was
defined as functional graft occlusion, a more rigorous
outcome than complete graft occlusion, which was used
for the 1-year comparison.
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Study population. Details of the study protocol have been
previously published (1–3) (Online Appendix). Patients
80 years of age undergoing nonemergent primary isolated
coronary bypass surgery with graftable triple-vessel disease
and an estimated left ventricular ejection fraction more than
35% were eligible for the study. The target coronary vessels
for the study grafts were the circumflex and the right coronary
arteries, which had70% diameter narrowing, were1.5 mm
n diameter, and were deemed to be of acceptable quality
ccording to visual assessment of the preoperative angiogram
y the operating surgeon. The study was approved by the
esearch ethics committee at each participating center. All
atients provided written informed consent.
andomization. Randomization was carried out in the
perating room with the use of sealed opaque envelopes
tratified by site with a randomly determined block size of 4
o 6. Specifically, within-patient randomization was per-
ormed whereby each patient was randomly allocated to
ndergo surgery according to 1 of 2 strategies; the radial
Figure 1 Patient Flow Chart
Flow chart of the 561 patients. Late graft angiography was performed in 269 patiertery was used for the right coro-
ary territory and the study SVG
as used for the circumflex region or
he radial artery was used for the
ircumflex territory and the study
VG was used for the right coronary
ystem. An internal thoracic artery
ITA) was used to bypass the left
nterior descending artery (LAD)
erritory. Additional grafts were
onstructed as necessary with single
ather than sequential grafts.
ollow-up angiography. Pa-
ients were approached to undergo invasive angiography at
east 5 years post-operatively. Computerized tomographic
raft angiography using a 64-multislice detector machine
computed tomography angiography [CTA]) was offered to
atients who withdrew consent for late invasive angiogra-
hy. Patients who declined to undergo 1-year angiography
ere also approached to undergo late angiography. Clini-
a mean of 7.7  1.5 years post-operatively.
Abbreviations
and acronyms
CTA  computed
tomography angiography
ITA  internal thoracic
artery
LAD  left anterior
descending artery
MACE  major adverse
cardiac event(s)
SVG  saphenous vein
graftnts at
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Late Radial Artery and SVG Patency July 3, 2012:28–35cally directed angiograms performed more than 36 months
post-operatively also counted toward the primary outcome.
Outcome measures. The primary study endpoint was the
proportion of radial artery and study SVG, which were
functionally occluded, defined as lack of Thrombolysis In
Myocardial Infarction flow grade 3, according to invasive
angiography. The secondary angiographic endpoint was the
proportion of study grafts that were completely occluded by
invasive angiography or CTA.
Baseline CharacteristicsTable 1 Baseline Characteristics
Characteristics
All Patients
(n  561, 13 Centers)
L
Mean age, yrs 61.0 8.5
Age 70 yrs 111 (19.8)
Female 75 (13.4)
Nonelective surgery 196 (34.9)
Preoperative CCS class
1 9 (1.6)
2 133 (23.7)
3 267 (47.6)
4 152 (27.1)
Previous myocardial infarction 264 (47.1)
History of CHF 18 (3.2)
Diabetes 148 (26.4)
Oral hypoglycemics 114 (20.3)
Insulin 34 (6.1)
Pre-operative hypertension 271 (48.3)
Pre-operative dyslipidemia 375 (66.8)
Current smoker 104 (18.5)
Pre-operative creatinine, mol/l 93.0 20.1
Peripheral vascular disease 50 (8.9)
Left ventricular grade
1 272 (48.5)
2 280 (49.9)
3 8 (1.4)
4 1 (0.2)
Target vessel stenosis
50% stenosis of left main coronary artery 49 (8.7)
Right coronary artery
70%–89% stenosis 172 (30.7)
90%–99% stenosis 161 (28.7)
100% stenosis 228 (40.6)
Circumflex artery
70%–89% stenosis 247 (44.0)
90%–99% stenosis 200 (35.7)
100% stenosis 114 (20.3)
Radial artery target vessel
70%–89% stenosis 222 (39.6)
90%–99% stenosis 174 (31.0)
100% stenosis 165 (29.4)
Saphenous vein target vessel
70%–89% stenosis 197 (35.1)
90%–99% stenosis 187 (33.3)
100% stenosis 177 (31.6)
Values are mean  SD or n (%). *p value compares the difference in the pre-operative demograph
centers that participated in late angiographic follow-up.
CCS  Canadian Cardiovascular Society; CHF  congestive heart failure.Follow-up angiograms were reviewed centrally by 5
cardiologists; an imaging cardiologist and a thoracic radiol-
ogist read the CT angiograms centrally. Each angiogram
was independently adjudicated in a blinded fashion by 2
committee members, with a third review in the case of
disagreement of the primary or secondary outcome.
The following late clinical events were recorded: death
from any cause, myocardial infarction, repeat coronary
surgery, and percutaneous coronary intervention. The com-
ase Participants
10, 9 Centers)
Late Angiography
(n  269)
No Late Angiography
(n  241) p Value*
0.9 8.3 60.4 8.0 61.4 8.7 0.15
71 (13.9) 32 (11.9) 39 (16.2) 0.16
68 (13.3) 41 (15.2) 27 (11.2) 0.18
77 (34.7) 93 (34.6) 84 (34.9) 0.95
0.63
9 (1.8) 4 (1.5) 5 (2.1)
21 (23.7) 59 (21.9) 62 (25.7)
45 (48.0) 137 (50.9) 108 (44.8)
35 (26.5) 69 (25.7) 66 (27.4)
35 (46.1) 124 (46.1) 111 (46.1) 0.99
14 (2.8) 5 (1.9) 9 (3.7) 0.20
44 (28.2) 83 (30.9) 61 (25.3) 0.17
10 (21.6) 67 (24.9) 43 (17.8)
34 (6.7) 16 (5.9) 18 (7.5)
54 (49.8) 121 (45.0) 133 (55.2) 0.02
43 (67.3) 189 (70.3) 154 (63.9) 0.11
93 (18.2) 43 (16.0) 50 (20.7) 0.16
3.1 19.2 92.5 17.5 93.8 21.0 0.46
43 (8.4) 16 (5.9) 27 (11.2) 0.03
0.31
39 (46.9) 133 (49.4) 106 (44.0)
62 (51.3) 131 (48.7) 131 (54.4)
8 (1.6) 4 (1.5) 4 (1.6)
1 (0.2) 1 (0.4) 0 (0)
49 (9.6) 24 (8.9) 25 (10.4) 0.58
0.91
58 (31.0) 84 (31.2) 74 (30.7)
43 (28.0) 73 (27.1) 70 (29.0)
09 (41.0) 112 (41.7) 97 (40.3)
0.25
34 (45.9) 115 (42.8) 119 (49.4)
80 (35.3) 102 (37.9) 78 (32.3)
96 (18.8) 52 (19.3) 44 (18.3)
0.41
05 (40.2) 105 (39.0) 100 (41.5)
58 (31.0) 82 (30.5) 76 (31.5)
47 (28.8) 82 (30.5) 65 (27.0)
0.72
87 (36.7) 94 (34.9) 93 (38.6)
65 (32.3) 93 (34.6) 72 (29.9)
58 (31.0) 82 (30.5) 76 (31.5)
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was defined as cardiac death, nonfatal myocardial infarction,
and any repeat revascularization procedure. Death was
considered to be due to cardiac causes unless a definite
noncardiac cause was identified. All clinical events were
reviewed centrally in a blinded fashion by a committee
consisting of 2 cardiologists and 1 cardiac surgeon.
Statistical analysis. The comparison between radial artery
and study SVG occlusion was performed on an intention-
to-treat basis using the McNemar’s test for paired propor-
tional data. An initial test for the treatment (radial artery or
SVG) by target vessel interaction was performed with
logistic regression. Freedom from late clinical events and
cumulative graft patency was summarized using Kaplan-
Meier analysis. A p value of 0.05 indicated statistical
significance. Statistical analysis was performed with SAS
version 9.2 (Cary, North Carolina).
Results
Patient population. Between November 1996 and January
001, 561 patients were enrolled from 12 university Cana-
ian centers and 1 center from New Zealand, of whom 440
nderwent angiography at 1 year post-operatively. Eleven
anadian centers agreed to participate in late clinical
ollow-up (n  529); 9 centers participated in the late
angiographic study (n  510) (Fig. 1). There were 358
patients who remained alive and eligible for late angiogra-
phy 5 years post-operatively. Altogether, 269 of the 358
patients (75%) underwent late angiography at a mean of
7.7  1.5 years after surgery (234 by invasive angiography
and 35 by CTA). The last study angiogram was performed
in October 2010. Angiography was performed per protocol
in 244 patients at 7.8  1.4 years and in 25 patients for
clinical reasons at 6.7  1.6 years following surgery. Table 1
Angiographic EndpointsTable 2 Angiographic Endpoints
Radia
TIMI flow grade*
3 206/23
2 2/23
1 5/23
0 21/23
Primary endpoint: functional graft occlusion (TIMI flow grade 0 or 1 or 2) 28/23
70%–89% proximal stenosis of native vessel disease 15/93
90% proximal stenosis of native vessel disease 13/14
Angiographic string sign* 8/23
Secondary endpoint: complete occlusion§ 24/26
70%–89% proximal stenosis of native vessel disease 12/10
90% proximal stenosis of native vessel disease 12/16
Values are n/n (%) or odds ratio (95% confidence interval [CI]). The primary and secondary angiogra
from invasive x-ray angiography only (n  234). †For comparison of radial artery grafts with 90
cclusion. ‡For comparison of saphenous vein grafts with90% proximal target vessel stenosis w
nd computed tomography angiography (n  269). For comparison of radial artery grafts with 
cclusion. ¶For comparison of saphenous vein grafts with 90% proximal target vessel stenosis with 9
TIMI  Thrombolysis In Myocardial Infarction.lists the baseline patient characteristics (see the Online
Appendix for additional details).
Post-operative management. Discharge medications in
529 patients were aspirin in 92%, anticoagulants in 9%,
lipid-lowering medications in 49%, beta-blockers in 70%,
and angiotensin-converting enzyme inhibitors or angioten-
sin receptor blockers in 10%. At the time of last follow-up
(mean medication follow-up 6.7  3.3 years), 83% were
taking aspirin, 9% were taking other antithrombotic medi-
cations, 77% were taking a lipid-lowering medication, 56%
were taking a beta-blocker, and 51% were taking an
angiotensin-converting enzyme inhibitor or angiotensin re-
ceptor blocker. Calcium-channel blockers were prescribed in
94% of patients at hospital discharge; 33% of patients contin-
ued to take calcium-channel blockers at last follow-up.
Angiographic endpoints. The treatment by target vessel
interaction was tested initially for the angiographic end-
points and was nonsignificant by logistic regression. The
primary endpoint of functional graft occlusion was reduced
in radial arteries compared with SVG (28 of 234 [12.0%] vs.
46 of 234 [19.7%]; p  0.03 by McNemar’s test) (Table 2).
Including the 3 patients with occlusion of both radial and
SVG at the 1-year study, late radial graft occlusion was
13.1% and SVG occlusion was 20.7%. Functional occlusion
of ITA grafts to the LAD was 9.6%. The on-treatment
results were identical to the intention-to-treat results. Cu-
mulative graft patency is presented in Figures 2A and 3A.
The frequency of the secondary endpoint of complete
graft occlusion was also significantly reduced in the radial
artery compared with SVGs (24 of 269 [8.9%] vs. 50 of 269
[18.6%]; p 0.002) (Table 2). Including the 3 patients with
oth study grafts occluded at 1 year, radial graft occlusion
as 9.9% compared with 19.5% for the SVGs. Correspond-
ng results for ITA grafts to the LAD were 5.9%. Cumu-
ative graft patency is presented in Figures 2B and 3B.
y Saphenous Vein Odds Ratio (95% CI)
Absolute Difference
(95% CI) p Value
0) 188/234 (80.3)
) 0/234 (0)
) 2/234 (0.9)
) 44/234 (18.8) 0.45 (0.25–0.80) 9.8% (3.4–16.4%) 0.003
0) 46/234 (19.7) 0.58 (0.34–0.97) 7.7% (0.8–14.6%) 0.03
)† 21/82 (25.6)‡
) 25/152 (16.4)
) 0/234 (0) 0.01
) 50/269 (18.6) 0.46 (0.26–0.77) 9.7% (3.7–15.8%) 0.002
4) 22/94 (23.4)¶
) 28/175 (16.0)
dpoints of the trial are presented. The reported p values are fromMcNemar’s test results. *Results
imal target vessel stenosis with 90% proximal target vessel stenosis, p  0.11, for functional
% proximal target vessel stenosis, p 0.09, for functional occlusion. §Results from invasive X-ray
oximal target vessel stenosis with 90% proximal target vessel stenosis, p  0.25, for completel Arter
4 (88.
4 (0.9
4 (2.1
4 (9.0
4 (12.
(16.1
1 (9.2
4 (3.4
9 (8.9
5 (11.
4 (7.3
phic en
% prox
ith90
90% pr0% proximal target vessel stenosis, p  0.14, for complete occlusion.
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Late Radial Artery and SVG Patency July 3, 2012:28–35Clinical endpoints. Table 3 provides the MACE for the
29 study patients. After 1 year, 32 patients had a specific
oncardiac cause of death; 21 had a cardiac cause. The
verall incidence of MACE was similar in patients who did
nd did not undergo late angiography (60 of 269 [22.3%] vs.
7 of 260 (18.1%]; p  0.23). Late survival is presented in
igure 4A and cardiac event–free survival in Figure 4B.
ardiac event–free survival excluding perioperative myocar-
ial infarction was 93.6  1.2% at 7.5 years and 80.4 
.8% at 10 years. Table 4 provides the results for adjudicated
Figure 2 Freedom From Functional
and Complete Graft Occlusion
Freedom from (A) functional and (B) complete radial
and saphenous vein graft (SVG) occlusion is presented.cardiac events according to the territory of the graft likely
responsible.
Discussion
The RAPS study is the first multicenter clinical trial
reporting radial graft patency beyond 5 years. In the other
Figure 3
Freedom From Functional and
Complete Radial Graft Occlusion
According to Target Vessel Stenosis Severity
Freedom from (A) functional and (B) complete radial graft occlusion is
presented according to the severity of the proximal target vessel stenosis.and larger multicenter CSP 474 VA trial (4), the radial
Values are n (%). The composite endpoint, major adverse cardiac events, is
surgery, and percutaneous coronary intervention (PCI).
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target as determined by the surgeon; they reported that at 1
year, complete graft occlusion was similar in radial and study
SVGs (11%)—a 5-year extension is underway. At 5.5 years,
the single-center RSVP (Radial Artery Versus Saphenous
Vein Patency) study from London, England, reported that
complete graft occlusion was markedly less frequent in
radial grafts compared with SVGs directed to the circumflex
territory (5). There was no apparent graft-by-territory
interaction in the RAPS study, indicating that the relative
benefit of the radial artery compared with the saphenous
vein applies to both the right and circumflex territories.
Graft patency was improved when the radial artery was
directed to a more severely narrowed target vessel. The
single-center Australian RAPCO (Radial Artery Patency
and Clinical Outcomes) study scheduled angiographic
follow-up within 5 years in a minority of patients and
between 5 and 10 years post-operatively in the majority;
they have published interim results from 5 to 10 years of
follow-up (6).
Athanasiou et al. (7) included both randomized trials and
observational studies in a meta-analysis to compare the
patency rates across different follow-up intervals—there
were 7 studies with a follow-up 5 years. We updated their
review with results from the RAPS study and new data
complete to April 2011 (6–8). Radial grafting was associ-
ated with a reduced rate of late graft occlusion compared
with saphenous veins (for observational and randomized
trials, odds ratio: 0.520, 95% confidence interval: 0.342 to
0.790, p  0.002 [Online Fig. 1]; and for randomized trials
alone, odds ratio: 0.491, 95% confidence interval: 0.314 to
0.766, p 0.002 [Online Fig. 2]) (see the Online Appendix
for additional details).
Two randomized clinical trials have reported that event-
free survival was greater in patients receiving a radial artery
(9,10). In the Stand-in-Y trial, event-free survival was
similar in patients who received a radial artery compared
with a second ITA graft (10). Two moderately large,
single-center observational studies using propensity scores
have recently been published (11,12). Late survival and
event-free survival was enhanced with the use of a radial
artery compared with a saphenous vein in 1 (11) but inferior
)
Days to 1 Yr
1 Yr to Last
Follow-Up Total Events
5 (0.9) 53 (10.0) 61 (11.5)
4 (0.8) 21 (4.0) 26 (4.9)
1 (0.2) 9 (1.7) 63 (11.9)
0 2 (0.4) 2 (0.4)
4 (0.8) 24 (4.5) 28 (5.3)
8 (1.5) 50 (9.5) 107 (20.2)
cardiac death, any nonfatal myocardial infarction, repeat coronaryMajor Adverse Cardiac Events (n  529)Table 3 Major Adverse Cardiac Events (n  529
Outcome <30 Days 31
Death 3 (0.6)
Death from cardiac causes 1 (0.2)
Nonfatal myocardial infarction 53 (10.0)
Repeat coronary surgery 0
PCI 0
Major adverse cardiac events 54 (10.2)Figure 4 Late Survival and Freedom From MACE
(A) Actuarial survival of the 529 patients is presented. (B) Freedom from
major adverse cardiac events (MACE) is presented for the 529 patients
who had late follow-up. MACE is defined as cardiac death, any myocardial
infarction, reoperative coronary surgery, or percutaneous coronary
reintervention.to a second ITA in the other (12).
as 80%
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angiographic outcomes, because all patients receive both
study grafts, it is weak for the evaluation of clinical out-
comes. Akin to coronary stent trials with target lesions or
target vessels, we attempted to evaluate whether cardiac
events following surgery could be attributed to one or other
study graft. Although descriptive and hypothesis generating,
our evaluation of adjudicated MACE events showed that
there were fewer clinical events assigned to the radial artery
than the study saphenous vein.
The incidence of perioperative myocardial infarction in
this study was 10%. The incidence of perioperative myocar-
dial infarction seen in the RAPS study is comparable to
results from recent multicenter trials of myocardial protec-
tion (8.2% in the MEND-CABG II [MC-1 to Eliminate
Necrosis and Damage in Coronary Artery Bypass Graft
Surgery II] trial, 10.3% in PRIMO-CABG [Pexelizumab
for Reduction of Infarction and Mortality in Coronary
Artery Bypass Graft Surgery] trial, and 18.6% in the
EXPEDITION [Na/H EXchange inhibition to Pre-
vent coronary Events in acute-cardiac conDITIONs] trial)
and 9.8% in the PREVENT IV (Project of Ex-vivo Vein
Graft Engineering via Transfection IV) trial (13–16). The
precise definitions of perioperative myocardial infarction
differed in the other studies, but were typically based on
marked creatine kinase-myocardial band (CK-MB) eleva-
tions, or with new Q waves in association with more modest
elevations of CK-MB; in all studies, the CK-MB thresholds
were much more conservative than the consensus universal
definition (17), suggesting that the incidence of periopera-
tive myocardial infarction was greater than these reported
values.
Study limitations. Patients with significant vascular dis-
ease and renal insufficiency were excluded, due to the
increased risks of protocol-directed research angiography.
Radial access coronary angiography was not widely practiced
when patients were recruited into the RAPS study. Patients
were screened with a pre-operative duplex scan of the forearm.
Despite pre-operative screening, the size, length, or quality of
the radial conduit was the primary reason for 5 of the protocol
violations and 1 of the crossovers.
Patients recruited into the RAPS study were generally of
Late Cardiac Outcomes and Study Graft Failure of Adjudicated CasTable 4 Late Cardiac Outcomes and Study Graft Failure of Adju
Adjudicated Outcomes
Radial Graft
Probably or Likely
Death from cardiac causes (n  2) 0
Nonfatal myocardial infarction (n  9) 2
Repeat coronary surgery (n  2) 0
PCI (n  22) 3
Patient totals (n  28) 4
The table shows the results of the adjudicated events. Events were classified using a 5-point scale
vein graft (SVG), another graft, or progression of native vessel disease. The numbers in the table re
potential causes. A patient could have more than 1 nonfatal event. Overall reviewer agreement w
PCI  percutaneous coronary intervention.low risk. Late angiography was not performed in 23% ofpatients who remained eligible (although MACE was only
15.7% in these patients), an additional 13% were excluded
for various medical conditions, and 8% were lost to follow-
up. The patients who underwent angiography had a lower
prevalence of hypertension and peripheral vascular disease
compared with patients who did not undergo angiography.
Furthermore, although the overall incidence of MACE was
similar in the patients who did and did not undergo late
angiography, nonfatal outcomes were more frequent in
patients who underwent late angiography while fatal events
occurred more frequently in the patients who did not.
Ascertainment bias may exist (see the Online Appendix for
additional details).
Lipid-lowering medications were prescribed in 49% of
patients at discharge and 77% at last follow-up; increased
utilization may have preferentially improved SVG patency.
Separate McNemar’s tests were performed; improvement in
radial patency compared with saphenous veins was observed
in patients on and off statins at last follow-up (see the
Online Appendix for additional details).
Conclusions
The RAPS study supports the use of the radial artery as a
second arterial conduit, or as a third arterial conduit in
association with both ITA grafts, particularly for patients
with high-grade target vessel proximal stenoses. The benefit
of the radial artery compared with a vein graft persists over
7.5 years.
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